用针对外糖脂抗原的抗独特型抗体进行口服免疫可预防实验性沙眼衣原体感染。

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.

作者信息

Whittum-Hudson J A, An L L, Saltzman W M, Prendergast R A, MacDonald A B

机构信息

Wilmer Ophthalmological Institute, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287-9142, USA.

出版信息

Nat Med. 1996 Oct;2(10):1116-21. doi: 10.1038/nm1096-1116.

DOI:10.1038/nm1096-1116

PMID:8837610

Abstract

Chlamydia trachomatis is the leading cause worldwide of preventable infectious blindness (trachoma) and sexually transmitted disease, including nongonoccocal urethritis and pelvic inflammatory disease. To date, no effective vaccine against C. trachomatis infection has been identified. A monoclonal anti-idiotypic antibody (anti-Id) to the chlamydial exoglycolipid antigen (GLXA) was tested in a murine model of ocular chlamydial infection for its ability to induce systemic immunity, which reduces microbiologic and clinical disease. The anti-Id to GLXA, delivered either systemically in soluble form or orally after encapsulation in poly(lactide) microspheres, induced significant protective immunity against ocular challenge of mice with a human biovar of C. trachomatis. Protection was associated with induction of anti-GLXA antibody and anti-chlamydial neutralizing antibody.

摘要

沙眼衣原体是全球可预防的感染性失明（沙眼）和性传播疾病（包括非淋菌性尿道炎和盆腔炎）的主要病因。迄今为止，尚未发现针对沙眼衣原体感染的有效疫苗。在眼部沙眼衣原体感染的小鼠模型中，测试了一种针对衣原体胞外糖脂抗原（GLXA）的单克隆抗独特型抗体（抗Id）诱导全身免疫的能力，这种免疫可减轻微生物学和临床疾病。以可溶性形式全身给药或以聚（丙交酯）微球包裹后口服的GLXA抗Id，可诱导对感染人生物变种沙眼衣原体的小鼠眼部攻击产生显著的保护性免疫。保护作用与抗GLXA抗体和抗衣原体中和抗体的诱导有关。